Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres
Neuro-Oncology · 07.03.2025 · 27 (3) · 654-667
DOI: 10.1093/neuonc/noae211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.10.2024. Verfasst von Jun Pyo Hong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor Translational Research Laboratory, Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Brain Neoplasms, Perphenazine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Korean Government, Pioneer Research Center Program.
Abstract (Originalsprache)
Background
Glioblastoma (GBM), a primary malignant brain tumor, has a poor prognosis, even with standard treatments such as radiotherapy and chemotherapy. In this study, we explored the anticancer effects of the synergistic combination of perphenazine (PER), a dopamine receptor D2/3 (DRD2/3) antagonist, and temozolomide (TMZ), a standard treatment for GBM, in patient-derived human GBM tumorspheres (TSs).
Methods
The biological effects of the combination of PER and TMZ in GBM TSs were assessed by measuring cell viability, ATP, stemness, invasiveness, and apoptosis. Changes in protein and mRNA expression were analyzed using western blotting and RNA sequencing. Co-administration of PER and TMZ was evaluated in vivo using a mouse orthotopic xenograft model.
Results
The Severance dataset showed that DRD2 and DRD3 expressions were higher in tumor tissues than in the tumor-free cortex of patients with GBM. DRD2/3 knockout by CRISPR/Cas9 in patient-derived human GBM TSs inhibited cell growth and ATP production. The combined treatment with PER and TMZ resulted in superior effects on cell viability and ATP assays compared to those in single treatment groups. Flow cytometry, western blotting, and RNA sequencing confirmed elevated apoptosis in GBM TSs following combination treatment. Additionally, the combination of PER and TMZ downregulated the expression of protein and mRNA associated with stemness and invasiveness. In vivo evaluation showed that combining PER and TMZ extended the survival period of the mouse orthotopic xenograft model.
Conclusions
The synergistic combination of PER and TMZ has potential as a novel combination treatment strategy for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Tumor Translational Research Laboratory, Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Physiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Premedical, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore.
- Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.
ORCID-Profile: Hun Ho Park, Seok-Gu Kang
Förderung
- National Research Foundation of Korea
- Korean Government
- Pioneer Research Center Program
- Ministry of Science
- ICT & Future Planning
- Yonsei University College of Medicine
- Korea Health Technology R&D Project
- Korea Health Industry Development Institute
Zitieren
APA
Hong, J. P., Choi, R. J., Shim, J. K., Kim, K., Kim, R. N., Cho, H., Kim, S. J., Kim, S., Kim, N. H., Park, H. H., Moon, J. H., Kim, E. H., Teo, W. Y., Chung, S., Chang, J. H., & Kang, S. G. (2025). Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres. Neuro-Oncology, 27(3), 654-667. https://doi.org/10.1093/neuonc/noae211
Vancouver
Hong JP, Choi RJ, Shim JK, Kim K, Kim RN, Cho H, et al. Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres. Neuro-Oncology. 2025;27(3):654-667. doi:10.1093/neuonc/noae211
BibTeX
@article{Hong2025,
author = {Hong, Jun Pyo and Choi, Ran Joo and Shim, Jin-Kyoung and Kim, Kibyeong and Kim, Ryong Nam and Cho, HyeJoung and Kim, Seo Jin and Kim, Sohyun and Kim, Nam Hwa and Park, Hun Ho and Moon, Ju Hyung and Kim, Eui Hyun and Teo, Wan-Yee and Chung, Seungsoo and Chang, Jong Hee and Kang, Seok-Gu},
title = {Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {3},
pages = {654--667},
doi = {10.1093/neuonc/noae211}
}
EUVIMED